ClinicalTrialsFinder
RecruitingNot ApplicableNCT07563036

JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil

Assessment of Janus Kinase 2 Expression in Patients With Androgenic Alopecia and Its Modulation by Topical Minoxidil Therapy.

Sponsor

Kasr El Aini Hospital

Enrollment

25 participants

Start Date

Feb 1, 2026

Study Type

INTERVENTIONAL

Summary

Androgenetic alopecia is a common form of progressive hair loss. This prospective single-arm pre-post interventional study aims to assess tissue Janus Kinase 2 (JAK2) expression in patients with androgenetic alopecia by comparing balding and non-balding scalp at baseline, and to evaluate changes in JAK2 expression in balding scalp after 3 months of topical minoxidil 5% therapy. Clinical response will be assessed using standardized trichoscopic parameters.

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 50 Years

Inclusion Criteria4

  • Male adults aged 18 to 50 years with androgenetic alopecia.
  • Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V.
  • Patients who are treatment-naive or willing to undergo an adequate washout period for prior hair loss therapies of at least 1 month.
  • Willing and able to provide written informed consent.

Exclusion Criteria6

  • Other types of hair loss, including inflammatory or scarring alopecia.
  • Inflammatory scalp dermatoses, such as psoriasis or seborrheic dermatitis.
  • Use of systemic immunosuppressants, JAK inhibitors, or systemic corticosteroids within the last 12 months.
  • History of severe systemic disease, including renal, cardiovascular, or hepatic disease.
  • Chemotherapy during the last 5 years.
  • Bleeding disorders.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTopical Minoxidil 5% Solution

Topical minoxidil 5% solution applied to the affected scalp areas for 12 weeks. Men will apply 1 cc twice daily and women will apply 1 cc once daily.

PROCEDUREScalp Punch Biopsy

Three 2 mm punch biopsies will be obtained during the study: one from the balding scalp area and one from the non-balding scalp area at baseline, and one from the balding scalp area after 12 weeks of treatment.

DIAGNOSTIC_TESTTissue JAK2 Protein Measurement by ELISA

Tissue samples obtained from scalp punch biopsies will be analyzed for Janus Kinase 2 (JAK2) protein levels using ELISA at baseline and after 12 weeks of treatment.

Locations(1)

Kasr El Aini Hospital

Cairo, Cairo Governorate, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07563036